These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37947355)

  • 1. Testicular cancer in 2023: Current status and recent progress.
    McHugh DJ; Gleeson JP; Feldman DR
    CA Cancer J Clin; 2024; 74(2):167-186. PubMed ID: 37947355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
    Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
    Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
    Kozakova K; Mego M; Cheng L; Chovanec M
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
    Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
    Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Management of Refractory Germ Cell Tumors.
    Abughanimeh O; Teply BA
    Curr Oncol Rep; 2021 Jul; 23(9):101. PubMed ID: 34269906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
    Veenstra CM; Vaughn DJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Dose Chemotherapy and Autologous Stem Cell Transplant.
    Adra N; Abonour R
    Urol Clin North Am; 2019 Aug; 46(3):439-448. PubMed ID: 31277738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
    Oing C; Lorch A
    Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases.
    Guo CC; Punar M; Contreras AL; Tu SM; Pisters L; Tamboli P; Czerniak B
    Am J Surg Pathol; 2009 Aug; 33(8):1173-8. PubMed ID: 19561445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Management of Disseminated Germ Cell Tumors.
    Lavoie JM; Kollmannsberger CK
    Urol Clin North Am; 2019 Aug; 46(3):377-388. PubMed ID: 31277732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive and timely chemotherapy, the key of success in testicular cancer.
    Fléchon A; Culine S; Droz JP
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):35-46. PubMed ID: 11164717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of advanced testicular cancer.
    Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
    JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy for male germ cell tumor.
    Hara I; Miyake H; Yamada Y; Takenaka A; Fujisawa M
    Int J Urol; 2006 Aug; 13(8):1037-44. PubMed ID: 16903926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.
    Miki T; Mizutani Y; Akaza H; Ozono S; Tsukamoto T; Terachi T; Naito K; Nonomura N; Hara I; Yoshida O;
    Int J Urol; 2007 Jan; 14(1):54-9. PubMed ID: 17199861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.
    Feldman DR; Voss MH; Jacobsen EP; Jia X; Suarez JA; Turkula S; Sheinfeld J; Bosl GJ; Motzer RJ; Patil S
    Cancer; 2013 Jul; 119(14):2574-81. PubMed ID: 23606402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
    Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
    Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab for the salvage treatment of desperate germ cell tumor: A case report.
    Aksun MS; Ucgul E; Sahin TK; Guven DC; Aksoy S
    J Oncol Pharm Pract; 2021 Sep; 27(6):1516-1519. PubMed ID: 33283628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current chemotherapeutic approaches for recurrent or refractory germ cell tumors.
    O'Carrigan B; Grimison P
    Urol Oncol; 2015 Aug; 33(8):343-54. PubMed ID: 25308563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
    Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
    Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.